<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        7-5328-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TRIVACIN 4.6MG/24H TRANSDERMAL PATCHES
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RIVASTIGMINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        9
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Transdermal use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Transdermal patch
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pouch
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        166.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Luye Pharma AG " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Luye Pharma AG 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Acino AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06DA03 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The active substance of Trivacin is rivastigmine. Rivastigmine belongs to a class of substances called cholinesterase inhibitors. In patients with Alzheimer&rsquo;s dementia, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a substance that allows nerve cells to communicate with each other). Rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase. By blocking these enzymes, Trivacin allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer&rsquo;s disease. Trivacin is used for the treatment of adult patients with mild to moderately severe Alzheimer&rsquo;s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">a. &nbsp;Do not use Trivacin - if you are allergic to rivastigmine (the active substance in Trivacin) or any of the other ingredients of this medicine (listed in section 6). - if you have ever had an allergic reaction to a similar type of medicine (carbamate derivatives). - if you have a skin reaction spreading beyond the patch size, if there is a more intense local reaction (such as blisters, increasing skin inflammation, swelling) and if it does not improve within 48 hours after removal of the transdermal patch. If this applies to you, tell your doctor and do not apply Trivacin transdermal patches.<br />b. Take special care Talk to your doctor before using Trivacin: - if you have, or have ever had, an irregular or slow heartbeat. - if you have, or have ever had, an active stomach ulcer. - if you have, or have ever had, difficulties in passing urine. - if you have, or have ever had, seizures. - if you have, or have ever had, asthma or a severe respiratory disease. - if you suffer from trembling. - if you have a low body weight. - if you have gastrointestinal reactions such as feeling sick (nausea), being sick (vomiting) and diarrhoea. You may become dehydrated (losing too much fluid) if vomiting or diarrhoea are prolonged. - if you have impaired liver function. If any of these apply to you, your doctor may need to monitor you more closely while you are on this medicine. If you have not applied a patch for more than three days, do not apply the next one before you have talked to your doctor.<br />Children and adolescents There is no relevant use of Trivacin in the paediatric population in the treatment of Alzheimer&rsquo;s disease.<br />c. Taking other medicines with Trivacin Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Trivacin might interfere with anticholinergic medicines some of which are medicines used to relieve stomach cramps or spasms (e.g. dicyclomine), to treat Parkinson&rsquo;s disease (e.g. amantadine) or to prevent motion sickness (e.g. diphenhydramine, scopolamine, or meclizine). Trivacin Patch should not be given at the same time as metoclopramide (a medicine used to relieve or prevent nausea and vomiting). Taking the two medicines together could cause problems such as stiff limbs and trembling hands. If you have to undergo surgery whilst using Trivacin transdermal patches, tell your doctor that you are using them because they may exaggerate the effects of some muscle relaxants during anaesthesia. Caution when Trivacin Patch is given together with beta-blockers (medicines such as atenolol used to treat hypertension, angina, and other heart conditions). Taking the two medicines together could cause problems such as slowing of the heartbeat (bradycardia) leading to fainting or loss of consciousness.<br />d. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. If you are pregnant, the benefits of using Trivacin must be assessed against the possible effects on your unborn child. Trivacin should not be used during pregnancy unless clearly necessary. You should not breast-feed during treatment with Trivacin transdermal patches.<br />e. &nbsp;Driving and using machines Your doctor will tell you whether your illness allows you to drive vehicles and use machines safely. Trivacin transdermal patches may cause fainting or severe confusion. If you feel faint or confused do not drive, use machines or perform any other tasks that require your attention.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always use Trivacin transdermal patches exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure. IMPORTANT: &bull; Take off the previous patch before putting ONE new patch on. &bull; Only one patch per day. &bull; Do not cut the patch into pieces. &bull; Press the patch firmly in place for at least 30 seconds using the palm of the hand.<br />How to start treatment Your doctor will tell you which Trivacin transdermal patch is most suitable for you. &bull; Treatment usually starts with Trivacin 4.6 mg/24 h. &bull; The recommended usual daily dose is Trivacin 9.5 mg/24 h. If well tolerated, the treating physician may consider increasing the dose to 13.3 mg/24 h. &bull; Only wear one Trivacin patch at a time and replace the patch with a new one after&nbsp;<br />&nbsp;24 hours. During the course of the treatment your doctor may adjust the dose to suit your individual needs. If you have not applied a patch for more than three days, do not apply the next one before you have talked to your doctor. Transdermal patch treatment can be resumed at the same dose if treatment is not interrupted for more than three days. Otherwise your doctor will restart your treatment on Trivacin 4.6 mg/24 h. Trivacin can be used with food and drink.<br />Where to apply your Trivacin transdermal patch &bull; Before you apply a patch, make sure that your skin is clean, dry and hairless, free of any powder, oil, moisturiser or lotion that could keep the patch from sticking to your skin properly, free of cuts, rashes and/or irritations. &bull; Carefully remove any existing patch before putting on a new one. Having multiple patches on your body could expose you to an excessive amount of this medicine which could be potentially dangerous. &bull; Apply ONE patch per day to ONLY ONE of the possible locations shown in the following diagrams: - left upper arm or right upper arm - left upper chest or right upper chest (avoid breast) - left upper back or right upper back - left lower back or right lower back&nbsp;</p><p dir="ltr">When changing the patch, you must remove the previous day&rsquo;s patch before you apply the new one to a different location of skin each time (for example on the right side of your body one day, then on the left side the next day, and on your upper body one day, then on your lower body the next day). Do not apply a new patch to the same skin area twice within&nbsp;<br />&nbsp;14 days.<br />How to apply your Trivacin transdermal patch Trivacin patches are thin, skin-coloured, plastic patches that stick to the skin. Each patch is sealed in a sachet that protects it until you are ready to put it on. Do not open the sachet or remove a patch until just before you apply it.<br />Carefully remove the existing patch before putting on a new one. For patients starting treatment for the first time and for patients restarting rivastigmine after treatment interruption, please begin with the second picture.<br />Each patch is sealed in its own protective sachet. You should only open the sachet when you are ready to apply the patch. Cut the sachet at both scissors marks, but not further than the indicated line. Tear the sachet to open. Do not cut the entire length of the sachet in order to avoid damaging of the patch.&nbsp;<br />Remove the patch from the sachet. Remove the cover sheet from the top, skin-coloured side of the patch and discard it. A protective liner covers the sticky side of the patch. Peel off one side of the protective liner and do not touch the sticky part of the patch with the fingers.<br />Put the sticky side of the patch on the upper or lower back, upper arm or chest and then peel off the second side of the protective liner.<br />Then press the patch firmly in place for at least 30 seconds using the palm of the hand to make sure that the edges stick well.<br />If it helps you, you may write, for example, the day of the week, the patch with a thin ball point pen.<br />The patch should be worn continuously until it is time to replace it with a new one. You may wish to experiment with different locations when applying a new patch, to find ones that are most comfortable for you and where clothing will not rub on the patch.<br />How to remove your Trivacin transdermal patch Gently pull at one edge of the patch to remove it slowly from the skin. In case the adhesive residue is left over on your skin, gently soak the area with warm water and mild soap or use baby oil to remove it. Alcohol or other dissolving liquids (nail polish remover or other solvents) should not be used. You should wash your hands with soap and water after removing the patch. In case of contact with eyes or if the eyes become red after handling the patch, rinse immediately with plenty of water and seek medical advice if symptoms do not resolve.<br />Can you wear your Trivacin transdermal patch when you are bathing, swimming, or in the sun? &bull; Bathing, swimming or showering should not affect the patch. Make sure the patch does not loosen during these activities. &bull; Do not expose the patch to any external heat sources (e.g. excessive sunlight, saunas, solarium) for long periods of time.<br />What to do if a patch falls off If a patch falls off, apply a new one for the rest of the day, then replace it at the same time as usual the next day.<br />When and for how long to apply your Trivacin transdermal patch &bull; To benefit from treatment, you must apply a new patch every day, preferably at the same time of day. &bull; Only wear one Trivacin patch at a time and replace the patch with a new one after&nbsp;<br />&nbsp;24 hours.<br />If you use more Trivacin than you should If you accidentally apply more than one patch, remove all the patches from your skin, then inform your doctor that you have accidentally applied more than one patch. You may require medical attention. Some people who have accidentally taken too much Trivacin have experienced feeling sick (nausea), being sick (vomiting), diarrhoea, high blood pressure and hallucinations. Slow heartbeat and fainting may also occur.<br />If you forget to use Trivacin If you find you have forgotten to apply a patch, apply one immediately. You may apply the next patch at the usual time the next day. Do not apply two patches to make up for the one that you missed.<br />If you stop using Trivacin Tell your doctor or pharmacist if you stop using the patch.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, Trivacin transdermal patches can cause side effects, although not everybody gets them.<br />You may have side effects more often when you start your medicine or when your dose is increased. Usually, the side effects will slowly go away as your body gets used to the medicine.<br />Take off your patch and tell your doctor straight away, if you notice any of the following side effects which could become serious:<br />Common (may affect up to 1 in 10 people) &bull; Loss of appetite &bull; Feeling dizzy &bull; Feeling agitated or sleepy &bull; Urinary incontinence (inability to retain adequate urine)<br />Uncommon (may affect up to 1 in 100 people) &bull; Problems with your heartbeat such as slow heartbeat &bull; Seeing things that are not really there (hallucinations) &bull; Stomach ulcer &bull; Dehydration (losing too much fluid) &bull; Hyperactivity (high level of activity, restlessness) &bull; Aggression<br />Rare (may affect up to 1 in 1,000 people) &bull; Falling<br />Very rare (may affect up to 1 in 10,000 people) &bull; Stiff arms or legs &bull; Trembling hands</p><p dir="ltr">Not known (frequency cannot be estimated from the available data) &bull; Allergic reaction where the patch was used, such as blisters or inflamed skin &bull; The signs of Parkinson&rsquo;s disease get worse &ndash; such as tremor, stiffness and shuffling &bull; Inflammation of the pancreas &ndash; signs include serious upper stomach pain, often with feeling sick (nausea) or being sick (vomiting) &bull; Fast or uneven heartbeat &bull; High blood pressure &bull; Fits (seizures) &bull; Liver disorders (yellow skin, yellowing of the whites of the eyes, abnormal darkening of the urine or unexplained nausea, vomiting, tiredness and loss of appetite) &bull; Changes in tests which show how well the liver is working &bull; Feeling restless &bull; Nightmares Take off your patch and tell your doctor straight away, if you notice any of the side effects above.<br />Other side effects seen with rivastigmine capsules or oral solution and which may occur with the patch:<br />Common (may affect up to 1 in 10 people) &bull; Too much saliva &bull; Loss of appetite &bull; Feeling restless &bull; Generally feeling unwell &bull; Trembling or feeling confused &bull; Increased sweating<br />Uncommon (may affect up to 1 in 100 people) &bull; Uneven heart rate (e.g. fast heart rate) &bull; Difficulty sleeping &bull; Accidental falls<br />Rare (may affect up to 1 in 1,000 people) &bull; Fits (seizures) &bull; Ulcer in the intestine &bull; Chest pain &ndash; this may be caused by heart spasm<br />Very rare (may affect up to 1 in 10,000 people) &bull; High blood pressure &bull; Inflammation of the pancreas &ndash; the signs include serious upper stomach pain, often with feeling sick (nausea) or being sick (vomiting) &bull; Bleeding in the gut &ndash; shows as blood in stools or when being sick &bull; Seeing things that are not there (hallucinations) &bull; Some people who have been violently sick have had tearing of the tube that connects your mouth with your stomach (oesophagus)<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">&bull; Keep this medicine out of the sight and reach of children. &bull; Do not use this medicine after the expiry date which is stated on the carton and sachet after EXP. The expiry date refers to the last day of that month. &bull; Do not store above 30 &deg;C. &bull; Keep the transdermal patch in the sachet until use. &bull; Do not use any patch that is damaged or shows signs of tampering. &bull; After removing a patch, fold it in half with the sticky sides on the inside and press them together. Return the used patch to its sachet and dispose of it in such a way that&nbsp;<br />&nbsp;children cannot handle it. Do not touch your eyes with your fingers and wash your hands with soap and water after removing the patch. If your community burns domestic&nbsp;<br />&nbsp;rubbish, you can dispose of the patch with your domestic rubbish. Otherwise, return used patches to a pharmacy, preferably in the original packaging.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Each transdermal patch releases 4.6 mg of rivastigmine per 24 hours. Each transdermal patch of 4.6 cm2 contains 6.9 mg of rivastigmine. Each transdermal patch releases 9.5 mg of rivastigmine per 24 hours. Each transdermal patch of 9.2 cm2 contains 13.8 mg of rivastigmine.<br />List of excipients Matrix: - poly [(2 - ethylhexyl)acrylate, vinylacetate] - medium molecular weight polyisobutene - high molecular weight polyisobutene - silica, colloidal anhydrous - paraffin, light liquid Backing liner: - polyethylene / thermoplastic resin / aluminium coated polyester film Release liner: - polyester film, fluoropolymer-coated Orange printing ink<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Transdermal patch Each transdermal patch is a thin, matrix - type transdermal patch. The outside of the backing layer is tan coloured. Each patch is printed in orange with “RIV - TDS 4.6 mg / 24 h”. Each patch is printed in orange with “RIV - TDS 9.5 mg / 24 h”.
Each child - resistant sachet is made of a paper / polyethylene terephthalate / aluminium / polyacrylnitrile multilaminated material. One sachet contains one transdermal patch. Each transdermal patch is protected by a cover sheet made of siliconised polyethylene terephthalate film. Available in packs containing 7, 30 or 42 sachets and in multipacks containing 60, 84 or 90 sachets. Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Marketing Authorisation Holder: Acino AG Am Windfeld 35 83714 Miesbach, Germany<br />Manufacturer: Luye Pharma AG Am Windfeld 35 83714 Miesbach, Germany<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 This leaflet was last approved in October 2018

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>المادة الفعَّالة بتريفاسين هي ريفاستيجمين.</p><p>ينتمي ريفاستيجمين إلى فئة من المواد تُسمى مثبطات الكولينستيراز. في المرضى المصابين بالخرف النَّاجم<br />عن مرض الزهايمر، تتلف بعض الخلايا العصبية في المخ، مما يتسبب في انخفاض مستويات الناقل العصبي<br />أسيتيل كولين )أحد المواد التي تسمح للخلايا العصبية بالتَّواصل مع بعضها البعض(. يعمل ريفاستيجمين من<br />خلال حصر الإنزيمات التي تحلل الأسيتيل كولين: أسيتيل كولين إستراز وبوتريل كولين إستراز. من خلال<br />حصر هذه الإنزيمات، يسمح تريفاسين بارتفاع مستويات الأسيتيل كولين في المخ، مما يُساعد على الحد<br />من أعراض مرض الزهايمر.<br />يُستخدم تريفاسين لعلاج المرضى البالغين المصابين بخرف بسيط إلى متوسط في الشدة ناجم عن مرض<br />الزهايمر، أحد اضطرابات المخ المُترقية التي تُؤثر تدريجيًّا على كل من الذاكرة والقدرات العقلية والسلوك</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>2 . قبل استخدام تريفاسين<br />أ . لا تستخدم تريفاسين في الحالات التَّالية:<br />- إذا كنت تعاني من حساسية تجاه ريفاستيجمين )المادة الفعَّالة بتريفاسين( أو تجاه أي مكون من<br />.) المكونات الأخرى بهذا الدَّواء )المدرجة في قسم: 6<br />- إذا أُصبت من قبل بتفاعلات حساسية تجاه نوع مماثل من الأدوية )مشتقات الكاربامات(.<br />- إذا كنت مُصابًا بتفاعل جلدي امتد ليتعدى نطاق حجم اللاصقة وإذا كان هناك تفاعل موضعي أكثر شدة<br />)على سبيل المثال: بثور، ازدياد حدة الالتهاب الجلدي، تورم( وإذا لم يحدث تحسن في غضون 48 ساعة<br />بعد إزالة اللاصقة الجلدية.<br />أخبر طبيبك إذا انطبق ذلك عليك واحرص على عدم استخدام لاصقات تريفاسين الجلدية.<br />ب . توخ حذرًا خاصًّا<br />تحدَّث إلى طبيبك قبل استعمال تريفاسين في الحالات التَّالية:<br />- إذا كنت تُعاني أو قد عانيت من قبل من عدم انتظام ضربات القلب أو تباطؤها.<br />- إذا كنت تُعاني أو قد عانيت من قبل من تقرح نشط بالمعدة.<br />- إذا كنت تُعاني أو قد عانيت من قبل من صعوبات في التبول.<br />- إذا كنت تُعاني أو قد عانيت من قبل من تشنجات.<br />- إذا كنت تُعاني أو قد عانيت من قبل من الربو أو أحد أمراض الجهاز التنفسي الشديدة.<br />- إذا كنت تعاني من الارتجاف.<br />- إذا كان وزن جسمك منخفضًا.<br />- إذا كنت تعاني من تفاعلات بالجهاز الهضمي مثل شعور بالإعياء )غثيان( أو إعياء )قيء( وإسهال. قد تعاني<br />من الجفاف )فقدان كمية كبيرة من السوائل( إذا دام القيء والإسهال لفترة طويلة.<br />- إذا كنت تُعاني من قصور بوظائف الكبد.<br />إذا انطبق عليك أيٌّ من ذلك، قد يتعين على طبيبك مراقبتك عن كثب أثناء استخدامك لهذا الدَّواء.<br />إذا لم تستخدم أيًّا من اللاصقات لأكثر من ثلاثة أيام، فلا تستخدم اللاصقة التَّالية المقرر استخدامها قبل<br />التَّحدث إلى طبيبك.<br />الأطفال والمراهقون<br />لا يوجد استخدام ذو صلة لتريفاسين في شريحة المرضى من الأطفال فيما يتعلق بعلاج مرض الزهايمر.<br />ت . تناوُل أدوية أخرى مع تريفاسين<br />يُرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.<br />قد يتداخل تريفاسين مع الأدوية المضادة للفعل الكوليني، والتي يستخدم بعضها للتخفيف من تقلصات<br />المعدة )على سبيل المثال: ديسِيكلُومِين( أو لعلاج مرض الشلل الرعَّاش )مرض باركنسون( )على سبيل المثال:<br />أمانتادين( أو للوقاية من داء الحركة )على سبيل المثال: داي فينهيدرامين أو سكوبولامين أو ميكليزين(.<br />ينبغي عدم إعطاء لاصقة تريفاسين بالتَّزامن مع ميتوكلوبراميد )أحد الأدوية التي تُستَخدَم للتخفيف من<br />الغثيان والقيء، أو للوقاية منهما(. قد يتسبب استخدام الدَّواءين معًا في مشاكل مثل تصلب الأطراف<br />وارتجاف باليدين.<br />إذا كان يتعين عليك الخضوع لجراحة بينما كنت تستخدم لاصقات تريفاسين الجلدية، أخبر طبيبك باستخدامك<br />لها؛ فقد تزيد اللاصقات من تأثير بعض مُرخيات العضلات أثناء التَّخدير.<br />ينبغي توخي الحذر عند وضع لاصقات تريفاسين بمصاحبة حاصرات بيتا )أدوية مثل: أتينولول الذي يُستخدم<br />لعلاج ارتفاع ضغط الدَّم والذبحة الصدرية وغير ذلك من حالات القلب(. قد يتسبب استخدام الدواءين معًا<br />في مشاكل مثل تباطؤ ضربات القلب مما يُؤدي إلى الإغماء أو فقدان الوعي.<br />ث . الحمل والرَّضاعة الطبيعية والخصوبة<br />إذا كنتِ حاملً أو مرضعًا، أو تعتقدين أنكِ حامل أو تخططين لذلك، فاستشيري طبيبك أو الصيدلي الخاص<br />بك قبل استعمال هذا الدَّواء.<br />إذا كنتِ حاملً، ينبغي تقييم فوائد استخدام تريفاسين في مقابل الآثار المُحتملة التي قد يتعرض لها جنينك<br />الذي لم يُولد بعد. لذا، يجب عدم استخدام تريفاسين أثناء فترة الحمل ما لم تكن هناك ضرورة ملحة لذلك.<br />ينبغي عليك عدم ممارسة الرضاعة الطبيعية أثناء فترة العلاج بلاصقات تريفاسين الجلدية.<br />ج . القيادة واستخدام الآلات<br />سيخبرك طبيبك إذا كان مرضك يسمح لك بقيادة المركبات واستخدام الآلات بشكل آمن أم لا. قد تسبب<br />لاصقات تريفاسين الجلدية إغماء أو ارتباكًا حادًّا. لا تمارس القيادة أو تستخدم الآلات أو تقم بأي مهام أخرى<br />تتطلب أن تكون منتبها إذا كنت تشعر بالضعف أو الارتباك.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>٣ . كيفية استخدام تريفاسين<br />استخدم تريفاسين دائمًا كما أخبرك طبيبك بالضبط. يُرجى مراجعة طبيبك أو الصيدلي أو الممرضة إذا لم<br />تكن متأكدًا من كيفية الاستعمال.<br />هام:<br />&bull; قم بنزع اللاصقة السابقة قبل وضع لاصقة جديدة.<br />&bull; استخدام لاصقة واحدة فقط في اليوم.<br />&bull; لا تقم بتجزئة اللاصقة.<br />&bull; اضغط على اللاصقة لتثبيتها في مكانها بإحكام لمدة 30 ثانية على الأقل باستخدام راحة اليد.<br />كيفية بدء العلاج<br />من بين لاصقات تريفاسين الجلدية، سيخبرك طبيبك بأيهم أنسب لك.<br />&bull; عادة ما يبدأ العلاج بتريفاسين 4.6 مجم/ 24 ساعة.<br />&bull; عادة ما تبلغ الجرعة اليومية الموصى بها من تريفاسين 9.5 مجم/ 24 ساعة. إذا تم تحمُّلها بشكل جيد،<br />قد يأخذ الطبيب المُعالِج بعين الاعتبار زيادة الجرعة إلى 13.3 مجم/ 24 ساعة.<br />&bull; ضع لاصقة واحدة من تريفاسين في المرة الواحدة واستبدل اللاصقة بواحدة جديدة بعد مرور 24 ساعة.<br />أثناء مسار العلاج، قد يعدّل طبيبك من الجرعة لكي تناسب احتياجاتك الفردية.<br />إذا لم تستخدم أيًّا من اللاصقات لأكثر من ثلاثة أيام، فلا تستخدم اللاصقة التَّالية المقرر استخدامها قبل<br />التَّحدث إلى طبيبك. يُمكِن استئناف العلاج باستخدام اللاصقة الجلدية بالجرعة نفسها إذا لم يتم إيقاف العلاج<br />لمدة تزيد عن ثلاثة أيام. خلاف ذلك، سيعيد طبيبك بدء علاجك بتريفاسين ٤٫٦ مجم / ۲٤ ساعة.<br />يمكن استخدام تريفاسين مع الأطعمة والمشروبات.<br />أين يمكن وضع لاصقة تريفاسين الجلدية؟<br />&bull; قبل استخدامك لإحدى اللاصقات، احرص على أن يكون جلدك نظيفًا وجافًا وبلا شعر ولا يُوجد به أي<br />مسحوق أو زيت أو مرطب للبشرة أو لوشن قد يحيل دون التصاق اللاصقة بالجلد كما ينبغي واحرص<br />على ألا يكون به جروح وطفح جلدي و/ أو تهيُّج.<br />&bull; قم بإزالة أي لاصقة موجودة قبل وضع أخرى جديدة. وجود العديد من اللاصقات على جسمك قد<br />يعرضك لكمية زائدة من هذا الدَّواء مما قد يكون خطيرًا.<br />&bull; استخدم لاصقة واحدة في اليوم في واحدة فقط من المواضع الممكنة المبينة في الرسومات البيانية<br />التَّالية:<br />- الجزء العلوي من الذراع الأيسر أو الجزء العلوي من الذراع الأيمن<br />- الجزء العلوي الأيسر من الصدر أو الجزء العلوي الأيمن من الصدر )تجنب الثدي(<br />- الجزء العلوي الأيسر من الظهر أو الجزء العلوي الأيمن من الظهر<br />- الجزء السفلي الأيسر من الظهر أو الجزء السفلي الأيمن من الظهر</p><p>عند تغيير اللاصقة، يجب عليك إزالة اللاصقة الخاصة باليوم السابق قبل وضع اللاصقة الجديدة في مكان<br />مختلف بالجلد كل مرة )على سبيل المثال: في الجانب الأيمن من جسمك في يوم ثم في الجانب الأيسر في<br />اليوم التَّالي وفي الجزء العلوي من الجسم في يوم ثم في الجزء السفلي من الجسم في اليوم التالي(. لا تضع<br />لاصقة جديدة في المنطقة نفسها من الجلد مرتين في غضون 14 يومًا.<br />كيفية استخدام لاصقة تريفاسين الجلدية<br />تُعد لاصقات تريفاسين لاصقات رقيقة وبلون الجلد ومصنوعة من البلاستيك وتلتصق بالجلد. كل لاصقة مغلفة<br />في كيس يحميها إلى أن تكون مستعدًّا لاستخدامها. لا تفتح الكيس أو تزل اللاصقة إلا قبل استخدامك لها<br />مباشرة.<br />قم بإزالة اللاصقة الموجودة برفق قبل وضع أخرى جديدة.<br />فيما يخص المرضى ممن سيبدؤون العلاج للمرة الأولى والمرضى ممن<br />سيعيدون بدء استخدام ريفاستيجمين بعد وقف العلاج، يُرجى البدء<br />بالصورة الثانية.<br />كل لاصقة مغلفة في كيس واق خاص بها. ينبغي عليك عدم فتح الكيس<br />إلا إذا كنت مستعدًّا لاستخدام اللاصقة.<br />قم بقطع الكيس عند علامتي القص لكن احرص على عدم تعدي الخط<br />المُوضح. قم بقطع الكيس لفتحه. لا تقم بقطع الكيس بأكمله لتفادي<br />إتلاف اللاصقة.<br />أخرج اللاصقة من الكيس.<br />قم بإزالة طبقة الغلاف من الجانب العلوي المطابق للون الجلد الخاص<br />باللاصقة وتخلص منها.<br />تُوجد طبقة واقية تغطي الجانب اللاصق من اللاصقة.<br />قم بتقشير جانب واحد من الطبقة الواقية ولا تلمس الجزء اللاصق من<br />اللاصقة بالأصابع.<br />ضع الجانب اللاصق من اللاصقة على الجزء العلوي أو السفلي من<br />الظهر، أو الجزء<br />العلوي من الذراع أو الصدر، ثم قم بتقشير الجانب الآخر من<br />الطبقة الواقية.<br />ثم اضغط على اللاصقة لتثبيتها في مكانها بإحكام لمدة 30 ثانية على<br />الأقل باستخدام راحة اليد؛<br />للحرص على التصاق الحواف جيدًا.<br />إن كان ذلك يُساعدك، يمكنك تدوين، على سبيل المثال، اليوم من الأسبوع<br />على اللاصقة باستخدام قلم حبر جاف رفيع.<br />ينبغي إبقاء اللاصقة بشكل متواصل إلى أن يحين موعد استبدالها بواحدة جديدة. قد ترغب في تجربة<br />مواضع مختلفة عند وضع لاصقة جديدة؛ للعثور على أماكن أكثر راحة لك وحيث لن تحتك الملابس باللاصقة.<br />كيفية إزالة لاصقة تريفاسين الجلدية<br />قم بشد إحدى حواف اللاصقة برفق لإزالتها بتأن من الجلد. إذا ما تبقى جزء من اللاصقة على جلدك، قم<br />بنقع تلك المنطقة برفق في ماء دافئ ممزوج بكمية بسيطة من الصابون أو استخدم زيت الأطفال لإزالتها.<br />ينبغي عدم استخدام الكحول أو سوائل الإذابة الأخرى )مزيل طلاء الأظافر أو غيره من المذيبات(. يجب<br />عليك غسل يديك بالماء والصابون بعد إزالة اللاصقة. في حال ملامسة العين أو إذا أصبحت العين حمراء<br />بعد مناولة اللاصقة، فاشطفها فورًا بالكثير من الماء واطلب المشورة الطبية في حال عدم زوال الأعراض.<br />هل يمكنك وضع لاصقة تريفاسين الجلدية عند الاستحمام أو السباحة أو التعرض لأشعة الشمس؟<br />&bull; لن يُؤثر الاستحمام أو السباحة أو الاغتسال على اللاصقة. احرص على ألا تتراخى اللاصقة أثناء ممارسة<br />هذه الأنشطة.<br />&bull; يجب عدم تعريض اللاصقة لأية مصادر حرارة خارجية )على سبيل المثال: أشعة الشمس المفرطة،<br />حمامات البخار، الغرف المشمسة( لفترات طويلة.<br />ما عليك فعله إذا سقطت إحدى اللاصقات<br />إذا سقطت اللاصقة، يجب وضع واحدة جديدة لبقية اليوم، ثم استبدالها في الوقت نفسه كالمعتاد في<br />اليوم التَّالي.<br />متى ينبغي استخدام لاصقات تريفاسين الجلدية؟ وإلى متى ينبغي استخدامها؟<br />&bull; لكي تستفيد من العلاج، يجب عليك استخدام لاصقة جديدة كل يوم، يُفضل أن يتم ذلك في الوقت نفسه<br />من اليوم.<br />&bull; ضع لاصقة واحدة من تريفاسين في المرة الواحدة واستبدل اللاصقة بواحدة جديدة بعد مرور 24 ساعة.<br />إذا استخدمت كمية أكثر مما يجب من تريفاسين<br />إذا استخدمت أكثر من لاصقة بطريق الخطأ، قم بإزالة جميع اللاصقات من على جلدك ثم أبلغ طبيبك<br />أنك استخدمت أكثر من لاصقة بطريق الخطأ. فقد تحتاج إلى الرعاية الطبية. تعرض بعض الأشخاص ممن<br />استخدموا تريفاسين كثيرًا بطريق الخطأ لشعور بالإعياء )غثيان(، وإعياء )قيء(، وإسهال، وارتفاع ضغط الدَّم<br />وهلاوس. قد يحدث أيضًا تباطؤ في ضربات القلب وإغماء.<br />إذا أغفلت استخدام تريفاسين<br />إذا أغفلت وضع إحدى اللاصقات، فضع واحدة على الفور. يمكنك وضع اللاصقة التَّالية في الوقت المعتاد من<br />اليوم التَّالي. لا تضع لاصقتين لتعويض اللاصقة التي نسيتها.<br />إذا توقفت عن استعمال تريفاسين<br />أخبر طبيبك أو الصيدلي الخاص بك إذا توقفت عن استعمال اللاصقة.<br />إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، استشر الطبيب أو الصيدلي الخاص بك.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثله مثل كافة الأدوية، يمكن لتريفاسين لاصقة جلدية أن يُسبب آثارًا جانبية، على الرَّغم من عدم حدوثها<br />لدى الجميع.<br />غالبًا ما قد تُصاب بآثار جانبية عندما تبدأ العلاج أو عند زيادة الجرعة الخاصة بك. عادة ما ستزول الآثار<br />الجانبية تدريجيًّا مع تعوّد الجسم على الدَّواء.<br />أزل اللاصقة وأخبر طبيبك على الفور إذا لاحظت أيًّا من الآثار الجانبية التَّالية والتي قد تصبح خطيرة:<br />شائعة )قد تُؤثر على ما يصل إلى شخص واحد من كل ١٠ أشخاص(<br />&bull; فقدان الشهية<br />&bull; شعور بالدوخة<br />&bull; شعور بهياج أو نعاس<br />&bull; سَلَسُ البَول )عدم القدرة على الاحتفاظ بالقدر الكافي من البول(<br />غير شائعة )قد تُؤثر على ما يصل إلى شخص واحد من كل ١٠٠ شخص(<br />&bull; مشاكل بضربات القلب الخاصَّة بك مثل تباطؤ ضربات القلب.<br />&bull; رؤية أشياء غير موجودة في الواقع )هلاوس(.<br />&bull; قرحة بالمعدة.<br />&bull; جفاف )فقدان كمية كبيرة من السوائل(.<br />&bull; فرط النشاط )ارتفاع مستوى النشاط، التململ(.<br />&bull; عدوانية.<br />نادرة )في ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص(<br />&bull; السقوط.<br />نادرة جدًّا )في ما يصل إلى شخص واحد من كل 10000 شخص(<br />&bull; تصلب بالذراعين أو الساقين.<br />&bull; ارتجاف باليدين.<br />غير معروفة )لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة(<br />&bull; تفاعلات حساسية حيث تم استخدام اللاصقة، مثل البثور أو التهاب الجلد.<br />&bull; تدهور علامات مرض الشلل الرعَّاش )مرض باركنسون( &ndash; مثل الارتعاش والتصلب وجر القدمين.<br />&bull; التهاب البنكرياس &ndash; تشمل العلامات ألمًا خطيرًا بالجزء العلوي من المعدة الذي غالبًا ما يكون مصحوبًا<br />بشعور بالإعياء )غثيان( أو إعياء )قيء(.<br />&bull; تسارع ضربات القلب أو عدم انتظامها<br />&bull; ارتفاع ضغط الدَّم<br />&bull; نوبات تشنجية<br />&bull; اضطرابات بالكبد )اصفرار الجلد، اصفرار بياض العينين، بول داكن بشكل غير طبيعي أو غثيان وقيء<br />وتعب وفقدان شهية لا مبرر لأي منهم(.<br />&bull; تغيُّرات في الاختبارات التي تُشير إلى مدى كفاءة عمل الكبد.<br />&bull; شعور بالتَّململ.<br />&bull; كوابيس.<br />قم بإزالة اللاصقة وأخبر طبيبك على الفور إذا لاحظت أيًّا من الآثار الجانبية المذكورة أعلاه.<br />آثار جانبية أخرى تمت ملاحظتها مع ريفاستيجمين كبسولات أو محلول فموي والتي قد تحدث مع اللاصقة:<br />شائعة )قد تُؤثر على ما يصل إلى شخص واحد من كل ١٠ أشخاص(<br />&bull; إفراز كمية كبيرة من اللعاب.<br />&bull; فقدان الشهية.<br />&bull; شعور بالتململ.<br />&bull; شعور عام بالإعياء.<br />&bull; ارتجاف أو شعور بالارتباك.<br />&bull; تعرق زائد.<br />غير شائعة )قد تؤثر على ما يصل إلى شخص واحد من كل ١٠٠ شخص(<br />&bull; عدم انتظام معدل ضربات القلب )على سبيل المثال: تسارع معدل ضربات القلب(.<br />&bull; صعوبة النوم.<br />&nbsp;&bull; سقوط عرضي.</p><p>نادرة )في ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص(<br />&bull; نوبات تشنجية.<br />&bull; قرحة بالأمعاء.<br />&bull; ألم بالصدر &ndash; قد يكون ذلك ناجمًا عن تشنج القلب.<br />نادرة جدًّا )في ما يصل إلى شخص واحد من كل 10000 شخص(<br />&bull; ارتفاع ضغط الدَّم.<br />&bull; التهاب البنكرياس &ndash;تشمل العلامات ألمًا خطيرًا بالجزء العلوي من المعدة الذي غالبًا ما يكون مصحوبًا<br />بشعور بالإعياء )غثيان( أو إعياء )قيء(.<br />&bull; نزيف بالأمعاء &ndash;يظهر على هيئة دم بالبراز أو عند الإصابة بإعياء.<br />&bull; رؤية أشياء غير موجودة )هلَوِس(.<br />&bull; عانى بعض الأشخاص ممن أُصيبوا بإعياء حاد من تمزق الأنبوب الذي يربط بين الفم والمعدة )المريء(.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يُحفظ هذا الدَّواء بعيدًا عن رؤية ومتناول الأطفال.<br />&bull; لا تستخدم هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكارتونية وعلى الكيس بعد كلمة<br />يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر. .&quot;EXP&quot;<br />&bull; لا تقم بالتَّخزين في درجة حرارة تتعدى 30 درجة مئوية.<br />&bull; احتفظ باللاصقة الجلدية في الكيس حتى يحين وقت الاستعمال.<br />&bull; لا تستخدم أي لاصقة تالفة أو يظهر عليها علامات العبث.<br />&bull; بعد إزالة اللاصقة، قم بطيها عند المنتصف واحرص على أن تكون الجوانب اللاصقة إلى الداخل ثم اضغط<br />على النصفين معًا. أعد اللاصقة المُستخدمة إلى الكيس الخاص بها وتخلص منها بطريقة تمنع الأطفال من<br />الوصول إليها. لا تلمس عينيك بأصابعك واغسل يديك بالماء والصابون بعد إزالة اللاصقة. إذا كان سكان<br />الحي الذي تقطن به يحرقون النفايات المنزلية، يمكنك التَّخلص من اللاصقة مع نفاياتك المنزلية. خلاف<br />ذلك، ينبغي عندئذ إعادة اللاصقات المُستخدمة إلى الصيدلية، ويُفضل أن تكون في عبوتها الأصلية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تفرز كل لاصقة جلدية 4.6 مجم من ريفاستيجمين كل 24 ساعة. تحتوي كل لاصقة جلدية بمقاس 4.6 سنتيمتر<br />مربع على 6.9 مجم من ريفاستيجمين.<br />تفرز كل لاصقة جلدية 9.5 مجم من ريفاستيجمين كل 24 ساعة. تحتوي كل لاصقة جلدية بمقاس 9.2 سنتيمتر<br />مربع على 13.8 مجم من ريفاستيجمين.</p><p>قائمة السواغات<br />القالب:<br />&bull; عديد ]) 2 - إيثيل هيكسيل( أكريلات، أسيتات الفينيل[<br />&bull; بولي إيزوبيوتين متوسط الوزن الجزيئي.<br />&bull; بولي إيزوبيوتين مرتفع الوزن الجزيئي.<br />&bull; سيليكا غروية غير مائية.<br />&bull; سائل بارافين خفيف.<br />الطبقة الظهرية:<br />&bull; بولي إيثيلين/ راتنجات لدائن حرارية/ غلاف رقيق من البوليستر المُغلَّف بالألومنيوم.<br />غشاء إطلاق الدَّواء:<br />&bull; غلاف رقيق من البوليستر، مُغطى ببوليمير فلوري.<br />حبر طباعة برتقالي اللون</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>لاصقة جلدية.<br />كل لاصقة جلدية عبارة عن لاصقة جلدية رقيقة، من النوع الذي يحتوي على قالب. الجزء الخارجي من الطبقة<br />الظهرية مُلوَّن باللون الأسمر الضارب إلى الصفرة.<br />.&quot;RIV - TDS 4.6 mg / 24 h&quot; مطبوع على كل لاصقة باللون البرتقالي<br />.&quot;RIV - TDS 9.5 mg / 24 h&quot; مطبوع على كل لاصقة باللون البرتقالي<br />كل كيس مقاوم لعبث الأطفال مصنوع من الورق/ البولي إيثيلين تيريفثالات/ الألومنيوم/ مادة البولي<br />أكريلنيتريل متعددة الرقائق.<br />يحتوي الكيس الواحد على لاصقة جلدية واحدة.<br />كل لاصقة جلدية يحميها غطاء مصنوع من غلاف رقيق من البولي إيثيلين تيريفثالات السيليكوني.<br />متوفر في عبوات تحتوي على 7 أو 30 أو 42 كيسًا وفي عبوات متعددة تحتوي على 60 أو 84 أو 90 كيسًا.<br />قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التَّسويق:<br />شركة أسينو أيه جي<br />أم فينفيلد 35<br />83714 ميزباخ،<br />ألمانيا<br />جهة التَّصنيع:<br />لويه فارما إيه جي<br />أم فينفيلد 35<br />83714 ميزباخ،<br />ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أآخر تاريخ اعتماد لهذه النشرة كان في أكتوبر 2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trivacin 4.6 mg/24 h transdermal patch 
Trivacin 9.5 mg/24 h transdermal patch 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
 Each transdermal patch releases 4.6 mg of rivastigmine per 24 hours. Each transdermal patch of  4.6 cm2 contains 6.9 mg of rivastigmine. Each transdermal patch releases 9.5 mg of rivastigmine per 24 hours. Each transdermal patch of 9.2 cm2 contains 13.8 mg of rivastigmine. 
 
For the full list of excipients, see section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Transdermal patch 
 
Each transdermal patch is a thin, matrix-type transdermal patch. The outside of the backing layer is tan coloured.  Each patch is printed in orange with “RIV-TDS 4.6 mg/24 h”. Each patch is printed in orange with “RIV-TDS 9.5 mg/24 h”. 
 
 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Symptomatic treatment of mild to moderately severe Alzheimer&rsquo;s dementia.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer&rsquo;s dementia. Diagnosis should be made according to current guidelines. Similar to any treatment initiated in patients with dementia, therapy with rivastigmine should&nbsp; only be started if a caregiver is available to regularly administer and monitor the treatment.</p><p dir="ltr">Posology</p><p dir="ltr">Transdermal patches&nbsp; : Rivastigmine in&nbsp; vivo release rates per 24 h Trivacin</p><p dir="ltr">4.6 mg/24 h: 4.6 mg</p><p dir="ltr">Trivacin 9.5 mg/24 h: 9.5 mg</p><p dir="ltr">Rivastigmine 13.3 mg/24 h* : 13.3 mg</p><p dir="ltr">&nbsp;</p><p dir="ltr">*The 13.3 mg/24 h dose strength cannot be achieved with this product. For conditions where this&nbsp; strength should be used, please refer to other rivastigmine products for which transdermal patches&nbsp; of the 13.3 mg/24 h strength are available.</p><p dir="ltr">Initial dose Treatment is started with 4.6 mg/24 h.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Maintenance dose After a minimum of four weeks of treatment and if well tolerated according to the treating physician, the dose of 4.6 mg/24 h should be increased to 9.5 mg/24 h, the daily recommended effective dose, which should be continued for as long as the patient continues to demonstrate therapeutic benefit.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Dose escalation&nbsp; 9.5 mg/24 h is the recommended daily effective dose which should be continued for as long as the patient continues to demonstrate therapeutic benefit. If well tolerated and only after a minimum of six months of treatment at 9.5 mg/24 h, the treating physician may consider increasing the dose to 13.3 mg/24 h in patients who have demonstrated a meaningful cognitive deterioration (e.g. decrease in the MMSE) and/or functional decline (based on physician judgement) while on the recommended daily effective dose of 9.5 mg/24 h (see section 5.1).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The clinical benefit of rivastigmine should be reassessed on a regular basis. Discontinuation should also be considered when evidence of a therapeutic effect at the optimal dose is no longer present.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment should be temporarily interrupted if gastrointestinal adverse reactions are observed until these adverse reactions resolve. Transdermal patch treatment can be resumed at the same dose if treatment is not interrupted for more than three days. Otherwise treatment should be re-initiated with 4.6 mg/24 h.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Switching from capsules or oral solution to transdermal patches Based on comparable exposure between oral and transdermal rivastigmine (see section 5.2), patients treated with rivastigmine capsules or oral solution can be switched to Trivacin transdermal patches as follows: &bull;&nbsp; A patient on a dose of 3 mg/day oral rivastigmine can be switched to 4.6 mg/24 h transdermal patches. &bull;&nbsp; A patient on a dose of 6 mg/day oral rivastigmine can be switched to 4.6 mg/24 h transdermal patches. &bull;&nbsp; A patient on a stable and well tolerated dose of 9 mg/day oral rivastigmine can be switched to 9.5 mg/24 h transdermal patches. If the oral dose of 9 mg/day has not been stable and well tolerated, a switch to 4.6 mg/24 h transdermal patches is recommended.&nbsp; &bull;&nbsp; A patient on a dose of 12 mg/day oral rivastigmine can be switched to 9.5 mg/24 h transdermal patches.</p><p dir="ltr">&nbsp;</p><p dir="ltr">After switching to 4.6 mg/24 h transdermal patches, provided these are well tolerated after a minimum of four weeks of treatment, the dose of 4.6 mg/24 h should be increased to 9.5 mg/24 h, which is the recommended effective dose.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">It is recommended to apply the first transdermal patch on the day following the last oral dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Special populations&nbsp; &bull; Paediatric population: There is no relevant use of rivastigmine in the paediatric population in the&nbsp; treatment of Alzheimer&rsquo;s disease.&nbsp; &bull; Patients with body weight below 50 kg: Particular caution should be exercised in titrating patients&nbsp; with body weight below 50 kg above the recommended effective dose of 9.5 mg/24 h (see section 4.4). They may experience more adverse reactions and may be more likely to discontinue due to&nbsp; adverse reactions.&nbsp; &bull; Hepatic impairment: Due to increased exposure in mild to moderate hepatic impairment as&nbsp; observed with the oral formulation, dosing recommendations to titrate according to individual&nbsp; tolerability should be closely followed.&nbsp; Patients with clinically significant hepatic impairment&nbsp; may experience more dose-dependent adverse reactions. Patients with severe hepatic impairment&nbsp; have not been studied. Particular caution should be exercised in titrating these patients (see&nbsp; sections 4.4 and 5.2).&nbsp; &bull; Renal impairment: No dose adjustment is necessary for patients with renal impairment (see&nbsp; section 5.2).&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Method of administration Transdermal patches should be applied once a day to clean, dry, hairless, intact healthy skin on the upper or lower back, upper arm or chest, in a place which will not be rubbed by tight clothing. It is not recommended to apply the transdermal patch to the thigh or to the abdomen due to decreased bioavailability of rivastigmine observed when the transdermal patch is applied to these areas of the body.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">The transdermal patch should not be applied to skin that is red, irritated or cut. Reapplication to the exact same skin location within 14 days should be avoided to minimise the potential risk of skin irritation.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients and caregivers should be instructed on important administration instructions:&nbsp; &bull; The previous day&rsquo;s patch must be removed before applying a new one every day (see section 4.9).&nbsp; &bull; The patch should be replaced by a new one after 24 hours. Only one patch should be worn at a&nbsp; time (see section 4.9).&nbsp; &bull; The patch should be pressed down firmly for at least 30 seconds using the palm of the hand until&nbsp; the edges stick well.&nbsp; &bull; If the patch falls off, a new one should be applied for the rest of the day, then it should be replaced&nbsp; at the same time as usual the next day.&nbsp; &bull; The patch can be used in everyday situations, including bathing and during hot weather.&nbsp; &bull; The patch should not be exposed to any external heat sources (e.g. excessive sunlight, saunas,&nbsp; solarium) for long periods of time.&nbsp; &bull; The patch should not be cut into pieces.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The use of this medicinal product is contraindicated in patients with known hypersensitivity to the active substance rivastigmine, to other carbamate derivatives or to any of the excipients listed in section 6.1. 
 
Previous history of application site reactions suggestive of allergic contact dermatitis with rivastigmine patch (see section 4.4). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The incidence and severity of adverse reactions generally increase with increasing doses, particularly at dose changes. If treatment is interrupted for more than three days, it should be re-initiated with &nbsp;4.6 mg/24 h.&nbsp;<br />&nbsp;<br />Misuse of the medicinal product and dosing errors resulting in overdose &nbsp;Misuse of the medicinal product and dosing errors with rivastigmine transdermal patch have resulted in serious adverse reactions; some cases have required hospitalisation, and rarely led to death (see section 4.9). Most cases of misuse of the medicinal product and dosing errors have involved not removing the old patch when putting on a new one and the use of multiple patches at the same time. Patients and their caregivers must be instructed on important administration instructions for rivastigmine transdermal patch (see section 4.2). &nbsp;<br />&nbsp;<br />Gastrointestinal disorders Gastrointestinal disorders such as nausea, vomiting and diarrhoea are dose-related, and may occur when initiating treatment and/or increasing the dose (see section 4.8). These adverse reactions occur more commonly in women. Patients who show signs or symptoms of dehydration resulting from prolonged vomiting or diarrhoea can be managed with intravenous fluids and dose reduction or discontinuation if recognised and treated promptly. Dehydration can be associated with serious outcomes.&nbsp;<br />&nbsp;<br />Weight loss &nbsp;Patients with Alzheimer&rsquo;s disease may lose weight whilst taking cholinesterase inhibitors, including rivastigmine. The patient&rsquo;s weight should be monitored during therapy with rivastigmine transdermal patches.&nbsp;<br />&nbsp;<br />Bradycardia &nbsp;Rivastigmine may cause bradycardia which constitutes a risk factor in the occurrence of torsade de pointes, predominantly in patients with risk factors. Caution is advised in patients at higher risk of developing torsade de pointes; for example, those with uncompensated heart failure, recent myocardial infarction, bradyarrhythmias, a predisposition to hypokalaemia or hypomagnesaemia, or concomitant use with medicinal products known to induce QT prolongation and/or torsade de pointes (see sections 4.5 and 4.8). &nbsp;<br />&nbsp;<br />Other adverse reactions &nbsp;Care must be taken when prescribing Trivacin transdermal patches: &bull; &nbsp;to patients with sick sinus syndrome or conduction defects (sino-atrial block, atrio-ventricular block) (see section 4.8); &bull; &nbsp;to patients with active gastric or duodenal ulcers or patients predisposed to these conditions because rivastigmine may cause increased gastric secretions (see section 4.8); &bull; &nbsp;to patients predisposed to urinary obstruction and seizures because cholinomimetics may induce or exacerbate these diseases; &bull; &nbsp;to patients with a history of asthma or obstructive pulmonary disease. &nbsp;<br />&nbsp;<br />Skin application site reactions &nbsp;Skin application site reactions may occur with rivastigmine patch and are usually mild or moderate in intensity. Patients and caregivers should be instructed accordingly.&nbsp;<br />&nbsp;<br />These reactions are not in themselves an indication of sensitisation. However, use of rivastigmine patch may lead to allergic contact dermatitis. &nbsp; Allergic contact dermatitis should be suspected if application site reactions spread beyond the patch size, if there is evidence of a more intense local reaction (e.g. increasing erythema, oedema, papules, vesicles) and if symptoms do not significantly improve within 48 hours after patch removal. In these cases, treatment should be discontinued (see section 4.3). &nbsp; Patients who develop application site reactions suggestive of allergic contact dermatitis to rivastigmine patch and who still require rivastigmine treatment should only be switched to oral rivastigmine after negative allergy testing and under close medical supervision. It is possible that some patients sensitised to rivastigmine by exposure to rivastigmine patch may not be able to take rivastigmine in any form. &nbsp;<br />&nbsp;<br />There have been rare post-marketing reports of patients experiencing allergic dermatitis (disseminated) when administered rivastigmine irrespective of the route of administration (oral, transdermal). In these cases, treatment should be discontinued (see section 4.3). &nbsp;<br />&nbsp;<br />Other warnings and precautions &nbsp;Rivastigmine may exacerbate or induce extrapyramidal symptoms.&nbsp;<br />&nbsp;<br />Contact with the eyes should be avoided after handling Trivacin transdermal patches (see section 5.3). Hands should be washed with soap and water after removing the patch. In case of contact with eyes or if the eyes become red after handling the patch, rinse immediately with plenty of water and seek medical advice if symptoms do not resolve.&nbsp;<br />&nbsp;<br />Special populations &bull; &nbsp;Patients with body weight below 50 kg may experience more adverse reactions and may be &nbsp;more likely to discontinue due to adverse reactions (see section 4.2). Carefully titrate and &nbsp;monitor these patients for adverse reactions (e.g. excessive nausea or vomiting) and consider &nbsp; &nbsp;reducing the maintenance dose to the 4.6 mg/24 h transdermal patch if such adverse reactions &nbsp;develop. &bull; &nbsp;Hepatic impairment: Patients with clinically significant hepatic impairment may experience more &nbsp;adverse reactions. Dosing recommendations to titrate according to individual tolerability must be &nbsp;closely followed. Patients with severe hepatic impairment have not been studied. Particular &nbsp;caution must be exercised in titrating these patients (see sections 4.2 and 5.2).&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No specific interaction studies have been performed with rivastigmine transdermal patches. &nbsp;<br />&nbsp;<br />As a cholinesterase inhibitor, rivastigmine may exaggerate the effects of succinylcholine-type muscle relaxants during anaesthesia. Caution is recommended when selecting anaesthetic agents. Possible dose adjustments or temporarily stopping treatment can be considered if needed.&nbsp;<br />&nbsp;<br />In view of its pharmacodynamic effects and possible additive effects, rivastigmine should not be given concomitantly with other cholinomimetic substances and might interfere with the activity of anticholinergic medicinal products (e.g. oxybutynin, tolterodine).&nbsp;<br />&nbsp;<br />Additive effects leading to bradycardia (which may result in syncope) have been reported with the&nbsp;combined use of various beta-blockers (including atenolol) and rivastigmine. Cardiovascular betablockers are expected to be associated with the greatest risk, but reports have also been received in patients using other beta-blockers. Therefore, caution should be exercised when rivastigmine is combined with beta-blockers and also other bradycardia agents (e.g.class III antiarrhythmic agents, calcium channel antagonists, digitalis glycoside, pilocarpin).&nbsp;<br />&nbsp;<br />Since bradycardia constitutes a risk factor in the occurrence of torsades de pointes, the combination of rivastigmine with torsades de pointes-inducing medicinal products such as antipsychotics i.e. some phenothiazines (chlorpromazine, levomepromazine), benzamides (sulpiride, sultopride, amisulpride, tiapride, veralipride), pimozide, haloperidol, droperidol, cisapride, citalopram, diphemanil, erythromycin IV, halofantrin, mizolastin, methadone, pentamidine and moxifloxacine should be observed with caution and clinical monitoring (ECG) may also be required.&nbsp;<br />&nbsp;<br />No pharmacokinetic interaction was observed between oral rivastigmine and digoxin, warfarin, diazepam or fluoxetine in studies in healthy volunteers. The increase in prothrombin time induced by warfarin is not affected by administration of oral rivastigmine. No untoward effects on cardiac conduction were observed following concomitant administration of digoxin and oral rivastigmine. &nbsp;<br />&nbsp;<br />Concomitant administration of rivastigmine with commonly prescribed medicinal products, such as antacids, antiemetics, antidiabetics, centrally acting antihypertensives, calcium channel blockers, inotropic agents, antianginals, non-steroidal anti-inflammatory agents, oestrogens, analgesics, benzodiazepines and antihistamines, was not associated with an alteration in the kinetics of rivastigmine or an increased risk of clinically relevant untoward effects. &nbsp;<br />&nbsp;<br />According to its metabolism, metabolic interactions with other medicinal products appear unlikely, although rivastigmine may inhibit the butyrylcholinesterase mediated metabolism of other substances.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pregnancy In pregnant animals, rivastigmine and /or metabolites crossed the placenta. It is not known if this occurs in humans. No clinical data on exposed pregnancies are available. In peri/postnatal studies in &nbsp;rats, an increased gestation time was observed. Rivastigmine should not be used during pregnancy unless clearly necessary.&nbsp;<br />&nbsp;<br />Breast feeding In animals, rivastigmine is excreted in milk. It is not known if rivastigmine is excreted into human milk. Therefore, women on rivastigmine should not breast-feed.&nbsp;<br />&nbsp;<br />Fertility No adverse effects of rivastigmine were observed on fertility or reproductive performance in rats (see section 5.3). Effects of rivastigmine on human fertility are not known.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Alzheimer&rsquo;s disease may cause gradual impairment of driving performance or compromise the ability to use machines. Furthermore, rivastigmine may induce syncope or delirium. As a consequence, rivastigmine has minor or moderate influence on the ability to drive and use machines. Therefore, in patients with dementia treated with rivastigmine, the ability to continue driving or operating complex machines should be routinely evaluated by the treating physician.&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Summary of the safety profile &nbsp;Application site skin reactions (usually mild to moderate application site erythema), are the most frequent adverse reactions observed with the use of rivastigmine transdermal patch. The next most common adverse reactions are gastrointestinal in nature including nausea and vomiting.&nbsp;<br />&nbsp;<br />Adverse reactions in Table 1 are listed according to MedDRA system organ class and frequency category. Frequency categories are defined using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).&nbsp;<br />&nbsp;<br />Tabulated list of adverse reactions &nbsp;Table 1 displays the adverse reactions reported in 1670 patients with Alzheimer&rsquo;s dementia treated in randomised, double-blind, placebo and active-controlled clinical studies with rivastigmine transdermal patches for a duration of 24-48 weeks and from post-marketing data.&nbsp;</p><p dir="ltr">Table 1</p><p dir="ltr">Infections and infestations &nbsp;</p><p dir="ltr">Common &nbsp; Urinary tract infection</p><p dir="ltr">Metabolism and nutrition disorders &nbsp;</p><p dir="ltr">Common &nbsp; Anorexia, decreased appetite &nbsp;</p><p dir="ltr">Uncommon &nbsp;Dehydration</p><p dir="ltr">Psychiatric disorders &nbsp;</p><p dir="ltr">Common &nbsp; Anxiety, depression, delirium, agitation &nbsp;</p><p dir="ltr">Uncommon &nbsp;Aggression &nbsp;</p><p dir="ltr">Not known &nbsp; Hallucinations, restlessness, nightmares</p><p dir="ltr">Nervous system disorders &nbsp;</p><p dir="ltr">Common &nbsp; Headache, syncope, dizziness &nbsp;</p><p dir="ltr">Uncommon &nbsp;Psychomotor hyperactivity &nbsp;Very rare &nbsp; Extrapyramidal symptoms &nbsp;</p><p dir="ltr">Not known &nbsp;Worsening of Parkinson&rsquo;s disease, seizure, tremor, somnolence</p><p dir="ltr">Cardiac disorders &nbsp;</p><p dir="ltr">Uncommon &nbsp; Bradycardia &nbsp;</p><p dir="ltr">Not known &nbsp;Atrioventricular block, atrial fibrillation, tachycardia, sick sinus syndrome</p><p dir="ltr">Vascular disorders &nbsp;</p><p dir="ltr">Not known &nbsp;Hypertension</p><p dir="ltr">Gastrointestinal disorders &nbsp;</p><p dir="ltr">Common &nbsp; Nausea, vomiting, diarrhoea, dyspepsia, abdominal pain &nbsp;</p><p dir="ltr">Uncommon &nbsp; Gastric ulcer &nbsp;</p><p dir="ltr">Not known &nbsp;Pancreatitis</p><p dir="ltr">Hepatobiliary disorders &nbsp;</p><p dir="ltr">Not known &nbsp;Hepatitis, elevated liver function tests</p><p dir="ltr">Skin and subcutaneous tissue disorders &nbsp;</p><p dir="ltr">Common &nbsp; Rash &nbsp;Not known &nbsp;Pruritus, erythema, urticaria, vesicles, allergic dermatitis (disseminated)</p><p dir="ltr">Renal and urinary disorders &nbsp;</p><p dir="ltr">Common &nbsp;Urinary incontinence</p><p dir="ltr">General disorders and administration site conditions &nbsp;</p><p dir="ltr">Common &nbsp;Application site skin reactions (e.g. application site erythema*, application site pruritus*, application site oedema*, application site dermatitis,&nbsp;</p><p dir="ltr">application site irritation), asthenic conditions (e.g. fatigue, asthenia), pyrexia, weight decreased&nbsp;</p><p dir="ltr">Rare</p><p dir="ltr">Fall&nbsp;</p><p dir="ltr">*In a 24-week controlled study in Japanese patients, application site erythema, application site &nbsp; &nbsp;oedema and application site pruritus were reported as &ldquo;very common&rdquo;.&nbsp;<br />&nbsp;<br />Description of selected adverse reactions &nbsp;When doses higher than 13.3 mg/24 h were used in the above-mentioned placebo-controlled study, insomnia and cardiac failure were observed more frequently than with 13.3 mg/24 h or placebo, suggesting a dose effect relationship. However, these events did not occur at a higher frequency with rivastigmine 13.3 mg/24 h transdermal patches than with placebo.&nbsp;<br />&nbsp;<br />The following adverse reactions have only been observed with rivastigmine capsules and oral solution and not in clinical studies with rivastigmine transdermal patches: malaise, confusion, sweating increased (common); duodenal ulcers, angina pectoris (rare); gastrointestinal haemorrhage (very rare); and some cases of severe vomiting were associated with oesophageal rupture (not known).&nbsp;<br />&nbsp;<br />Skin irritation In double-blind controlled clinical trials, application site reactions were mostly mild to moderate in severity. The incidence of application site skin reactions leading to discontinuation was &le;2.3% in patients treated with rivastigmine transdermal patches. The incidence of application site skin reactions leading to discontinuation was higher in the Asian population with 4.9% and 8.4% in the Chinese and Japanese population respectively.&nbsp;<br />&nbsp;<br />In a 24-week double-blind, placebo-controlled clinical trial, skin reactions were measured at each visit using a skin irritation rating scale. When observed in patients treated with rivastigmine transdermal patches, skin irritation was mostly slight or mild in severity. It was rated as severe in &le;2.2% of patients in these studies and in &le;3.7% of patients treated with rivastigmine transdermal patches in a Japanese study.&nbsp;<br />&nbsp;<br />Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.&nbsp;<br />&nbsp;<br />&nbsp;<br />&minus; To reports any side effect(s): &nbsp;<br />&bull; Saudi Arabia: &nbsp;<br />&nbsp;<br />&nbsp;&minus;The National Pharmacovigilance and Drug Safety Centre (NPC) &nbsp;o Fax: +966-11-205-7662 &nbsp;o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-23342340. &nbsp;o Toll free phone: 8002490000 &nbsp;o E-mail: npc.drug@sfda.gov.sa &nbsp;o Website: www.sfda.gov.sa/npc &nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Symptoms Most cases of accidental overdose of oral rivastigmine have not been associated with any clinical signs or symptoms and almost all of the patients concerned continued rivastigmine treatment 24 hours after the overdose. &nbsp;<br />&nbsp;<br />Cholinergic toxicity has been reported with muscarinic symptoms that are observed with moderate poisonings such as miosis, flushing, digestive disorders including abdominal pain, nausea, vomiting and diarrhoea, bradycardia, bronchospasm and increased bronchial secretions, hyperhidrosis, involuntary urination and/or defecation, lacrimation, hypotension and salivary hypersecretion.&nbsp;<br />&nbsp;<br />In more severe cases nicotinic effects might develop such as muscular weakness, fasciculations, seizures and respiratory arrest with possible fatal outcome.&nbsp;<br />&nbsp;<br />Additionally there have been post-marketing cases of dizziness, tremor, headache, somnolence, confusional state, hypertension, hallucinations and malaise. Overdose with rivastigmine transdermal patch resulting from misuse/dosing errors (application of multiple patches at a time) has been reported in the post-marketing setting and rarely in clinical trials. &nbsp;<br />&nbsp;<br />Management As rivastigmine has a plasma half-life of about 3.4 hours and a duration of acetylcholinesterase inhibition of about 9 hours, it is recommended that in cases of asymptomatic overdose all Trivacin transdermal patches should be removed immediately and no further transdermal patch should be applied for the next 24 hours. In overdose accompanied by severe nausea and vomiting, the use of antiemetics should be considered. Symptomatic treatment for other adverse reactions should be given as necessary. &nbsp;<br />&nbsp;<br />In massive overdose, atropine can be used. An initial dose of 0.03 mg/kg intravenous atropine sulphate is recommended, with subsequent doses based on clinical response. Use of scopolamine as an antidote is not recommended.&nbsp;<br />&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: psychoanaleptics, anticholinesterases, ATC code: N06DA03&nbsp;<br />&nbsp;<br />Rivastigmine is an acetyl- and butyrylcholinesterase inhibitor of the carbamate type, thought to facilitate cholinergic neurotransmission by slowing the degradation of acetylcholine released by functionally intact cholinergic neurones. Thus, rivastigmine may have an ameliorative effect on cholinergic-mediated cognitive deficits in dementia associated with Alzheimer&rsquo;s disease. &nbsp;<br />&nbsp;<br />Rivastigmine interacts with its target enzymes by forming a covalently bound complex that temporarily inactivates the enzymes. In healthy young men, an oral 3 mg dose decreases&nbsp;acetylcholinesterase (AChE) activity in CSF by approximately 40% within the first 1.5 hours after administration. Activity of the enzyme returns to baseline levels about 9 hours after the maximum inhibitory effect has been achieved. In patients with Alzheimer&rsquo;s disease, inhibition of AChE in CSF by oral rivastigmine was dose-dependent up to 6 mg given twice daily, the highest dose tested. Inhibition of butyrylcholinesterase activity in CSF of 14 Alzheimer patients treated by oral rivastigmine was similar to the inhibition of AChE activity.&nbsp;<br />&nbsp;<br />Clinical studies in Alzheimer&rsquo;s dementia The efficacy of rivastigmine transdermal patches in patients with Alzheimer&rsquo;s dementia has been demonstrated in a 24-week double-blind, placebo-controlled core study and its open-label extension phase and in a 48-week double blind comparator study. &nbsp;24-week placebo-controlled study &nbsp;Patients involved in the placebo-controlled study had an MMSE (Mini-Mental State Examination) score of 10&ndash;20. Efficacy was established by the use of independent, domain-specific assessment tools which were applied at regular intervals during the 24-week treatment period. These include the ADAS-Cog (Alzheimer&rsquo;s Disease Assessment Scale &ndash; Cognitive subscale, a performance-based measure of cognition) and the ADCS-CGIC (Alzheimer&rsquo;s Disease Cooperative Study &ndash; Clinician&rsquo;s Global Impression of Change, a comprehensive global assessment of the patient by the physician incorporating caregiver input), and the ADCS-ADL (Alzheimer&rsquo;s Disease Cooperative Study &ndash; Activities of Daily Living, a caregiver-rated assessment of the activities of daily living including personal hygiene, feeding, dressing, household chores such as shopping, retention of ability to orient oneself to surroundings as well as involvement in activities related to finances). The 24-week results for the three assessment tools are summarised in Table 2.&nbsp;</p><p dir="ltr">Table 2&nbsp;<br />ITT-LOCF population&nbsp;<br />Rivastigmine transdermal patches 9.5 mg/24 h N = 251&nbsp;<br />Rivastigmine capsules 12 mg/day &nbsp;N = 256&nbsp;<br />Placebo N = 282&nbsp;<br />ADAS-Cog &nbsp; &nbsp; (n=248) (n=253) (n=281) Mean baseline &plusmn; SD 27.0 &plusmn; 10.3 27.9 &plusmn; 9.4 28.6 &plusmn; 9.9 Mean change at week 24 &plusmn; SD -0.6 &plusmn; 6.4 -0.6 &plusmn; 6.2 1.0 &plusmn; 6.8 p-value versus placebo 0.005*1 0.003*1 &nbsp;ADCS-CGIC &nbsp; &nbsp; (n=248) (n=253) &nbsp;(n=278) Mean score &plusmn; SD 3.9 &plusmn; 1.20 3.9 &plusmn;&plusmn; 1.25 4.2 &plusmn; 1.26 p-value versus placebo 0.010*2 0.009*2 &nbsp;ADCS-ADL &nbsp; &nbsp; (n=247) (n=254) &nbsp;(n=281) Mean baseline &plusmn; SD 50.1 &plusmn; 16.3 49.3 &plusmn; 15.8 49.2 &plusmn; 16.0 Mean change at week 24 &plusmn; SD -0.1 &plusmn; 9.1 -0.5 &plusmn; 9.5 -2.3 &plusmn; 9.4 p-value versus placebo 0.013*1 0.039*1 &nbsp;* p&le;0.05 versus placebo ITT: Intent-To-Treat; LOCF: Last Observation Carried Forward 1 Based on ANCOVA with treatment and country as factors and baseline value as a covariate. Negative ADAS-Cog changes indicate improvement. Positive ADCS-ADL changes indicate improvement. 2 Based on CMH test (van Elteren test) blocking for country. ADCS-CGIC scores &lt;4 indicate improvement.&nbsp;<br />&nbsp;<br />&nbsp;<br />The results for clinically relevant responders from the 24-week placebo-controlled study are provided in Table 3. Clinically relevant improvement was defined a priori as at least 4-point improvement on the ADASCog, no worsening on the ADCS-CGIC, and no worsening on the ADCS-ADL.&nbsp;<br />&nbsp;<br />&nbsp;<br />&nbsp;<br />Table 3 &nbsp;Patients with clinically significant response (%)&nbsp;<br />ITT-LOCF population&nbsp;<br />Rivastigmine transdermal patches 9.5 mg/24 h N = 251&nbsp;<br />Rivastigmine capsules 12 mg/day&nbsp;<br />&nbsp;<br />N = 256&nbsp;<br />Placebo&nbsp;<br />&nbsp;<br />&nbsp;<br />N = 282&nbsp;<br />At least 4 points improvement on ADAS-Cog with no worsening on ADCSCGIC and ADCS-ADL&nbsp;<br />&nbsp;<br />p-value versus placebo&nbsp;<br />17.4&nbsp;<br />&nbsp;<br />&nbsp;<br />&nbsp;<br />&nbsp;<br />0.037*&nbsp;<br />19.0&nbsp;<br />&nbsp;<br />&nbsp;<br />&nbsp;<br />&nbsp;<br />0.004*&nbsp;<br />10.5&nbsp;<br />* p&le;0.05 versus placebo&nbsp;<br />&nbsp;<br />As suggested by compartmental modelling, 9.5 mg/24 h transdermal patches exhibited exposure similar to that provided by an oral dose of 12 mg/day.&nbsp;<br />&nbsp;<br />48-week active comparator controlled study &nbsp;Patients involved in the active comparator controlled study had an initial baseline MMSE score of 1024. The study was designed to compare the efficacy of the 13.3 mg/24 h transdermal patch against the 9.5 mg/24 h transdermal patch during a 48-week double-blind treatment phase in Alzheimer&rsquo;s disease patients who demonstrated functional and cognitive decline after an initial 24-48 week open-label treatment phase while on a maintenance dose of 9.5 mg/24 h transdermal patch. Functional decline was assessed by the investigator and cognitive decline was defined as a decrease in the MMSE score of &gt;2 points from the previous visit or a decrease of &gt;3 points from baseline. Efficacy was established by the use of ADAS-Cog (Alzheimer&rsquo;s Disease Assessment Scale &ndash; Cognitive subscale, a performance-based measure of cognition) and the ADCS-IADL (Alzheimer&rsquo;s Disease Cooperative Study &ndash; Instrumental Activities of Daily Living) assessing instrumental activities which include maintaining finances, meal preparation, shopping, ability to o rient oneself to surroundings, ability to be left unattended. The 48-week results for the two assessment tools are summarised in Table 4. &nbsp;<br />&nbsp;<br />Table 4 Population/Visit Rivastigmine patch 15 cm2 N = 265&nbsp;<br />Rivastigmine patch 10 cm2 N = 271&nbsp;<br />Rivastigmine patch &nbsp;15 cm2&nbsp;<br />&nbsp;<br />Rivastigmine patch &nbsp;10 cm2&nbsp;<br />&nbsp;<br />&nbsp; &nbsp;n Mean n Mean DLSM 95% Cl p-value ADAS-Cog LOCF &nbsp;Baseline 264 34.4 268 34.9 &nbsp; &nbsp; DB-week 48 Value 264 38.5 268 39.7 &nbsp; &nbsp; &nbsp;Change 264 4.1 &nbsp; &nbsp; 268 4.9 -0.8 (-2.1, 0.5) 0.227 ADCS-IADL LOCF &nbsp;Baseline 265 27.5 271 25.8 &nbsp; &nbsp; Week 48 Value 265 23.1 271 19.6 &nbsp; &nbsp; &nbsp;Change 265 -4.4 271 -6.2 2.2 (0.8, 3.6) 0.002*&nbsp;<br />&nbsp;<br />&nbsp;<br />CI &ndash; confidence interval. &nbsp;DLSM &ndash; difference in least square means. &nbsp;LOCF &ndash; Last Observation Carried Forward. &nbsp;ADAS-cog scores: A negative difference in DLSM indicates greater improvement in rivastigmine 15 cm2 as compared to rivastigmine 10 cm2. &nbsp;ADCS-IADL scores: A positive difference in DLSM indicates greater improvement in rivastigmine 15 cm2 as compared to rivastigmine 10 cm2. &nbsp;N is the number of patients with an assessment at baseline (last assessment in the initial open-label phase) and with at least 1 post-baseline assessment (for the LOCF). &nbsp;The DLSM, 95% CI, and p-value are based on an ANCOVA (analysis of covariance) model adjusted for country and baseline ADAS-cog score. &nbsp;* p&lt;0.05 &nbsp;Source: Study D2340-Table 11-6 and Table 11-7&nbsp;<br />&nbsp;<br />The European Medicines Agency has waived the obligation to submit the results of studies with Rivastigmine in all subsets of the paediatric population in the treatment of Alzheimer&rsquo;s dementia (see section 4.2 for information on paediatric use).&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Absorption Absorption of rivastigmine from rivastigmine transdermal patches is slow. After the first dose, detectable plasma concentrations are observed after a lag time of 0.5-1 hour. Cmax is reached after 1016 hours. After the peak, plasma concentrations slowly decrease over the remainder of the 24-hour period of application. With multiple dosing (such as at steady state), after the previous transdermal patch is replaced with a new one, plasma concentrations initially decrease slowly for about 40 minutes on average, until absorption from the newly applied transdermal patch becomes faster than elimination, and plasma levels begin to rise again to reach a new peak at approximately 8 hours. At steady state, trough levels are approximately 50% of peak levels, in contrast to oral administration, with which concentrations fall off to virtually zero between doses. Although less pronounced than with the oral formulation, exposure to rivastigmine (Cmax and AUC) increased over-proportionally by a factor of 2.6 and 4.9 when escalating from 4.6 mg/24 h to 9.5 mg/24 h and to 13.3 mg/24 h, respectively. The fluctuation index (FI), a measure of the relative difference between peak and trough concentrations ((Cmax-Cmin)/Cavg), was 0.58 for rivastigmine 4.6 mg/24 h transdermal patches, 0.77 for rivastigmine 9.5 mg/24 h transdermal patches and 0.72 for rivastigmine 13.3 mg/24 h transdermal patches, thus demonstrating a much smaller fluctuation between trough and peak concentrations than for the oral formulation (FI = 3.96 (6 mg/day) and 4.15 (12 mg/day)).&nbsp;<br />&nbsp;<br />The dose of rivastigmine released from the transdermal patch over 24 hours (mg/24 h) cannot be directly equated to the amount (mg) of rivastigmine contained in a capsule with respect to plasma concentration produced over 24 hours.&nbsp;<br />&nbsp;<br />The single-dose inter-subject variability in rivastigmine pharmacokinetic parameters (normalised to dose/kg bodyweight) was 43% (Cmax) and 49% (AUC0-24h) after transdermal administration versus 74% and 103%, respectively, after the oral form. The inter-patient variability in a steady-state study in Alzheimer&rsquo;s dementia was at most 45% (Cmax) and 43% (AUC0-24h) after use of the transdermal patch, and 71% and 73%, respectively, after administration of the oral form.&nbsp;<br />&nbsp;<br />A relationship between active substance exposure at steady state (rivastigmine and metabolite NAP226-90) and bodyweight was observed in Alzheimer&rsquo;s dementia patients. Compared to a patient with a body weight of 65 kg, the rivastigmine steady-state concentrations in a patient with a body&nbsp;<br />weight of 35 kg would be approximately doubled, while for a patient with a body weight of 100 kg the concentrations would be approximately halved. The effect of bodyweight on active substance exposure suggests special attention to patients with very low body weight during up-titration (see section 4.4).&nbsp;<br />&nbsp;<br />Exposure (AUC&infin;) to rivastigmine (and metabolite NAP266-90) was highest when the transdermal patch was applied to the upper back, chest, or upper arm and approximately 20&ndash;30% lower when applied to the abdomen or thigh.&nbsp;<br />&nbsp;<br />There was no relevant accumulation of rivastigmine or the metabolite NAP226-90 in plasma in patients with Alzheimer&rsquo;s disease, except that plasma levels were higher on the second day of transdermal patch therapy than on the first.&nbsp;<br />&nbsp;<br />Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%). It readily crosses the bloodbrain barrier and has an apparent volume of distribution in the range of 1.8-2.7 l/kg.&nbsp;<br />&nbsp;<br />Biotransformation Rivastigmine is rapidly and extensively metabolised with an apparent elimination half-life in plasma of approximately 3.4 hours after removal of the transdermal patch. Elimination was absorption rate limited (flip-flop kinetics), which explains the longer t&frac12; after transdermal patch (3.4 h) versus oral or intravenous administrations (1.4 to 1.7 h). Metabolism is primarily via cholinesterase-mediated hydrolysis to the metabolite NAP226-90. In vitro, this metabolite shows minimal inhibition of acetylcholinesterase (&lt;10%). &nbsp;<br />&nbsp;<br />Based on in vitro studies, no pharmacokinetic interaction is expected with medicinal products metabolised by the following cytochrome isoenzymes: CYP1A2, CYP2D6, CYP3A4/5, CYP2E1, CYP2C9, CYP2C8, CYP2C19, or CYP2B6. Based on evidence from animal studies, the major cytochrome P450 isoenzymes are minimally involved in rivastigmine metabolism. Total plasma clearance of rivastigmine was approximately 130 litres/h after a 0.2 mg intravenous dose and decreased to 70 litres/h after a 2.7 mg intravenous dose, which is consistent with the non-linear, overproportional pharmacokinetics of rivastigmine due to saturation of its elimination.&nbsp;<br />&nbsp;<br />The metabolite-to-parent AUC&infin; ratio was around 0.7 after transdermal patch administration versus 3.5 after oral administration, indicating that much less metabolism occurred after dermal compared to oral treatment. Less NAP226-90 is formed following application of the transdermal patch, presumably because of the lack of presystemic (hepatic first pass) metabolism, in contrast to oral administration.&nbsp;<br />&nbsp;<br />Elimination Unchanged rivastigmine is found in trace amounts in the urine; renal excretion of the metabolites is the major route of elimination after transdermal patch administration. Following administration of oral 14C-rivastigmine, renal elimination was rapid and essentially complete (&gt;90%) within 24 hours. Less than 1% of the administered dose is excreted in the faeces.&nbsp;<br />&nbsp;<br />A population pharmacokinetic analysis showed that nicotine use increases the oral clearance of rivastigmine by 23% in patients with Alzheimer&rsquo;s disease (n=75 smokers and 549 non-smokers) following rivastigmine oral capsule doses for up to 12 mg/day.&nbsp;<br />&nbsp;<br />Older people&nbsp;<br />&nbsp;<br />Age had no impact on the exposure to rivastigmine in Alzheimer&rsquo;s disease patients treated with rivastigmine transdermal patches.&nbsp;<br />&nbsp;<br />Hepatic impairment &nbsp;No study was conducted with rivastigmine transdermal patches in subjects with hepatic impairment. After oral administration, the Cmax of rivastigmine was approximately 60% higher and the AUC of rivastigmine was more than twice as high in subjects with mild to moderate hepatic impairment than in healthy subjects.&nbsp;<br />&nbsp;<br />Following a single 3 mg or 6 mg oral dose, the mean oral clearance of rivastigmine was approximately 46-63% lower in patients with mild to moderate hepatic impairment (n=10, Child-Pugh score 5-12, biopsy proven) than in healthy subjects (n=10).&nbsp;<br />&nbsp;<br />Renal impairment No study was conducted with rivastigmine transdermal patches in subjects with renal impairment. &nbsp;Based on population analysis, creatinine clearance did not show any clear effect on steady state concentrations of rivastigmine or its metabolite. No dose adjustment is necessary in patients with renal impairment (see section 4.2).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Oral and topical repeated-dose toxicity studies in mice, rats, rabbits, dogs and minipigs revealed only effects associated with an exaggerated pharmacological action. No target organ toxicity was observed. Oral and topical dosing in animal studies was limited due to the sensitivity of the animal models used.&nbsp;<br />&nbsp;<br />Rivastigmine was not mutagenic in a standard battery of in vitro and in vivo tests, except in a chromosomal aberration test in human peripheral lymphocytes at a dose exceeding 104 times the foreseen clinical exposure. The in vivo micronucleus test was negative. The major metabolite NAP226-90 also did not show a genotoxic potential.&nbsp;<br />&nbsp;<br />No evidence of carcinogenicity was found in oral and topical studies in mice and in an oral study in rats at the maximum tolerated dose. The exposure to rivastigmine and its metabolites was approximately equivalent to human exposure with highest doses of rivastigmine capsules and transdermal patches.&nbsp;<br />&nbsp;<br />In animals, rivastigmine crosses the placenta and is excreted into milk. Oral studies in pregnant rats and rabbits gave no indication of teratogenic potential on the part of rivastigmine. In oral studies with male and female rats, no adverse effects of rivastigmine were observed on fertility or reproductive performance of either the parent generation or the offspring of the parents. Specific dermal studies in pregnant animals have not been conducted.&nbsp;<br />&nbsp;<br />Rivastigmine transdermal patches were not phototoxic and considered to be a non-sensitiser. In some other dermal toxicity studies, a mild irritant effect on the skin of laboratory animals, including controls, was observed. This may indicate a potential for rivastigmine transdermal patches to induce mild erythema in patients. A mild eye/mucosal irritation potential of rivastigmine was identified in a rabbit study. Therefore, the patient/caregiver should avoid contact with the eyes after handling of the patch (see section 4.4).&nbsp;<br />&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Matrix: - poly [(2-ethylhexyl)acrylate, vinylacetate] &nbsp; &nbsp;- medium molecular weight polyisobutene - high molecular weight polyisobutene &nbsp;- silica, colloidal anhydrous &nbsp;- paraffin, light liquid &nbsp;Backing liner: - polyethylene/thermoplastic resin/aluminium coated polyester film Release liner: - polyester film, fluoropolymer-coated Orange printing ink&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">To prevent interference with the adhesive properties of the transdermal patch, no cream, lotion or powder should be applied to the skin area where the medicinal product is to be applied.&nbsp;<br />&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Do not store above 30 &ordm;C.</p><p dir="ltr">Do not freeze.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Each child-resistant sachet is made of a paper / polyethylene terephthalate / aluminium / polyacrylnitrile multilaminated material. One sachet contains one transdermal patch. Each transdermal patch is protected by a cover sheet made of siliconised polyethylene terephthalate film.&nbsp;<br />&nbsp;<br />Available in packs containing 7, 30 or 42 sachets and in multipacks containing 60, 84 or 90 sachets. Not all pack sizes may be marketed.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Used transdermal patches should be folded in half, with the adhesive side inwards, placed in the original sachet and discarded safely and out of the reach and sight of children. Any used or unused transdermal patches should be disposed of in accordance with local requirements or returned to the pharmacy.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Acino AG Am Windfeld 35  83714 Miesbach
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2016 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>